Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md. and SUZHOU, China, March 15, 2022 /PRNewwire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and product pipeline at the Oligonucleotide &...

Related Keywords

China ,Boston ,Massachusetts ,United States ,Suzhou ,Jiangsu ,Nigel Yip ,Bunny Lee ,Dmitry Samarsky ,Alexis Feinberg ,Patrick Lu ,Company Galahead ,Sirnaomics Ltd ,Congress Opening ,Revere Hotel Boston Common ,Cambridge Healthtech Institute ,Also Present ,Precision Therapeutics ,Sirnaomics Chief Technology Officer ,Triggers Composed ,Sirnaomics Chief Technology ,Revere Hotel Boston ,Executive Director ,Technology Officer ,Financial Officer ,Media Contact ,